MIRA
INFORM REPORT
|
Report Date : |
29.06.2012 |
IDENTIFICATION DETAILS
|
Name : |
SHANGHAI NEW HUALIAN PHARMACEUTICAL CO.,LTD. |
|
|
|
|
Registered Office : |
Tower A, 15Fl, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
24.11.2010 |
|
|
|
|
Com. Reg. No.: |
310120001818348 |
|
|
|
|
Legal Form : |
Limited Liabilities Company |
|
|
|
|
Line of Business : |
Manufacture and sales of pharmaceuticals. |
|
|
|
|
No. of Employees : |
600 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name
|
SHANGHAI NEW HUALIAN PHARMACEUTICAL
CO.,LTD. |
Currency in this report
is Chinese Yuan unless otherwise stated.
Exchange Rate: 1
USD=6.37Chinese Yuan
"--"in
this report indicates "unavailable" due to insufficient information
or "no comments"
ORDER
INFORMATION
|
name |
Shanghai New Hualian Pharmaceutical Co
Ltd. |
|
address |
217 Minle Road Shanghai 201419 |
Note:
The
address provided in the order is SC’s factory address. SC’s office address is
as listed in the report.
EXECUTIVE
SUMMARY
|
DATE OF
establishment |
Nov 24th,
2010 |
|
Aic Registration
No. |
310120001818348 |
|
REGISTERED LEGAL
FORM |
limited liabilities company |
|
REGISTERED
CAPITAL |
73,714,286.00 |
|
main BUSINESS |
Sales of
pharmaceuticals. |
|
employees |
600 |
|
import and export
permits |
yes |
|
credit rating |
CR4 |
|
base Credie limit |
1,000,000.00 |
|
EXCHANGE RATE |
1 Usd=6.37CNY
(JUN.27th, 2012) |
|
Registered
Address |
No.217, Minle Rd, Xinhuo Development zone,
Haiwan Town, Fengxian Dist, Shanghai |
|
Zip Code |
201419 |
|
|
|
|
Business Address |
Tower A, 15Fl, Zhaofeng Huanqiu Mansion,
No.1800, Zhongshan West Rd, Xuhui Dist, Shanghai |
|
Zip Code |
200235 |
|
Telephone |
86 21 64403190 |
|
Fax |
86 21 64403190-8003 |
|
|
|
|
SIC Code (China) |
2720 manufacture of chemical medicine
preparation |
REGISTRATION
|
Name
(English) |
SHANGHAI NEW HUALIAN
PHARMACEUTICAL CO.,LTD. |
|
Date
of Establishment |
Nov 24th,
2010 |
|
Registry |
Administration
Bureau of Industry and Commerce – Fengxian (Shanghai) |
|
Legal
Representative |
Zhou Qiuhuo |
|
AIC Registration
Number |
310120001818348 |
|
Registered
Legal Form |
Limited Liabilities Company |
|
Registered
Capital |
73,714,286.00 |
|
Operating
Duration |
From
2010-11-24 to -- |
|
Business
Scope |
Manufacture
of tablet, hard capsule, bulk pharmaceutical chemicals, etc; Import
and export of goods and technologies. |
Limited
liabilities co.
This
form of business in PR China is defined as a legal person. Its registered
capital is contributed jointly by at least two shareholders and no more than
fifty. Shareholders bear limited liability to the extent of shareholding, and
the co. is liable for its debts only to extent of its total assets. The
characteristics of this form of co. are as follows:
Upon
the establishment of the co., an investment certificate is issued to the each
of shareholders.
The
board of directors is comprised of three to thirteen members.
The
minimum registered capital for a co. is listed as follows:
-manufacturing
co. : RMB 500,000.00
-trading
&wholesaling co. : RMB 500,000.00
-retailing
co. : RMB 300,000.00
-consultancy
& service co. : RMB 100,000.00
Shareholders
may take their capital contributions in cash or by means of tangible assets or
intangible assets such as industrial property and non-patented technology.
Cash
contributed by all shareholders must account for at least 50% of the registered
capital while contribution by intangible assets must not exceed 20% of the
registered capital.
Existing
shareholders have pre-exemption right to purchase shares of the co. offered for
sale by the other shareholders and to subscribe for the newly increased
registered capital of the co.
REGISTRATION
INFO: AVAILABLE
FINANCIAL
REPORTS: AVAILABLE
FIELD
INVESTIGATION
1. SC’s business income comes mainly from pharmaceuticals
including bulk pharmaceutical chemicals, tablet, capsules, oral solid ferment
preparation, etc. Its sales business is developed both directly and indirectly
to its end customers. SC has distributors and commercial agents in many cities
of China and its products are sold both domestically and internationally. The
industry of pharmaceuticals is an industry with fierce competition. There are a
lot of similar enterprises in the local place as SC’s competitors. SC’s
predecessor company is SHANGHAI PHARMACEUTICALS GROUP NEW HUALIAN
PHARMACEUTICAL FACTORY which has long operation history. Hence it has
accumulated certain amount of customers and enjoys certain popularity in
domestic market. Generally speaking, SC’s competitiveness is above average in
the local industry.
2. Shanghai
City, SC’s location has the largest foreign trade port and industrial base in
China. It is the economic, technology, industrial, financial, trade, exhibition
and shipping center of China with highly developed economy. As a domestic owned
enterprise dealing with sales of pharmaceuticals, SC enjoys no favorable policy
provided by the local government.
SHAREHOLDERS
AND SHARES
N/A
AFFILIATE(S)
No affiliates of subject company is found after checking.
MANAGEMENT
|
Name |
Zhou Qiu-huo |
|
Gender |
Male |
|
Title |
Chairman and General
manager. |
|
Education |
-- |
|
Working experience |
He is at the same time chairman
of ZHEJIANG KAIDI PHARMACEUTICALS CO. LTD. He has over 10 years’ working
experience and over 10 years’ management experience. |
NUMBER OF EMPLOYEES
Employees:
600
Management
Staff: 50
Recent
recruitment: Yes
|
Job-hunting websites |
Job title |
Number |
|
http://jobs.zhaopin.com/shanghai/%E4%BA%A7%E5%93%81%E4%B8%93%E5%91%98_342869820250189.htm |
Sales support director. |
1 |
|
http://jobs.zhaopin.com/shanghai/%E4%BA%A7%E5%93%81%E7%BB%8F%E7%90%86_342869820250198.htm |
Sales management director. |
1 |
|
http://jobs.zhaopin.com/shanghai/%E7%94%9F%E4%BA%A7%E6%80%BB%E7%9B%91_342869820250220.htm |
Manufacturing director. |
1 |
|
http://jobs.zhaopin.com/shanghai/%E8%B4%A2%E5%8A%A1%E4%B8%BB%E7%AE%A1_342869820250205.htm |
Financial staff. |
1 |
BANKERS INFORMATION
N/A
OFFICE FACILITIES
|
Geographic Location |
Tower A, 15Fl, Zhaofeng Huanqiu
Mansion, No.1800, Zhongshan West Rd, Xuhui Dist, Shanghai |
|
Area |
500 square meters |
|
Environment |
Office building. |
|
Traffic condition |
Convenient (closed to Neihuan
Gaojia Rd, Yishan Rd, Zhongshan West Rd, etc.) |
|
Purpose |
Office. |
|
Property Ownership |
Rented |
|
Factory |
No.217, Minle Rd, Xinhuo
Development Zone, Haiwan Town, Fengxian Dist, Shanghai |
|
Factory Area |
200,000 square meters. |
WEBSITE
|
Website |
http://www.nhl-pharm.com/ |
|
E-mail |
sales@nhl-pharm.com |
|
Operation status |
Operational |
|
Copyright |
Copyright reserved by SC. |
|
Language |
Chinese and English. |
TRADEMARKS
|
Total trademark |
2 |
|
Registration No. |
9490941 |
|
Registration date |
May 20th, 2011 |
|
Image |
|
|
|
|
|
Registration No. |
9490942 |
|
Registration date |
May 20th, 2011 |
|
Image |
|
PATENTS
|
Total patents |
1 |
|
Application No. |
201110452920.3 |
|
Application date |
Dec 29th,
2011 |
|
Patent name |
Preparation method
of zoledronic acid. |
MAIN
PRODUCTS & SERVICES
|
Main
business |
Manufacture
and sales of pharmaceuticals. |
|
Products
and services |
SC’s
predecessor company is SHANGHAI PHARMACEUTICALS GROUP NEW HUALIAN
PHARMACEUTICAL FACTORY and was reorganized to change to the present company
in 2010. It mainly deals with manufacture and sales of pharmaceutical
products including bulk pharmaceutical chemicals, tablets, capsules, oral
solid preparation, etc. SC’s main products include betamethasone valerate,
megestrol acetate, mifepristone tablets, mometasone furoate cream, dramamine,
pyraloximi iodidum, betamethasone, beclometasone, etc. |
|
Picture
of specific products |
-- |
|
Annual
production capacity |
-- |
|
Plants
and equipments |
It
has advanced international testing equipments, fermentation tanks, pipelines,
agitated reactors, boiling drying equipments, refrigerators, etc which worth
over 20 million CNY. |
|
Awards
& Honors |
-- |
|
Certificates
/ licenses |
Its
products have passed USA FDA certification, Europe EDQM certification, etc. |
SALES
INFORMATION
|
Domestic sales |
80% |
|
Regions |
All over China |
|
Major domestic clients |
SHANGHAI
PHARMACEUTICAL (GROUP) CORP; SHANGHAI LUOSHI PHARMACEUTICALS CO. LTD, etc. |
|
Competitors |
SHANDONG XINHUA
PHARMACEUTICALS CO. LTD; SHANGHAI QIANGSHENG PHARMACEUTICALS CO. LTD; XIUZHENG
PHARMACEUTICAL GROUP CO. LTD BEIJIGN XIUZHENG PHARMACEUTICAL CO. LTD; NORTH
CHINA PHARMACEUTICAL GROUP CORPORATION, etc.
|
|
Payment terms |
Prompt payment; on credit |
|
Export |
20% |
|
Regions |
Asia, USA, Europe, etc. |
|
Major overseas clients |
-- |
|
Payment terms |
L/C, T/T |
|
SC’s pharmaceutical products are mainly sold to domestic and overseas
distributors, drugstores, hospitals, etc. Its predecessor company is SHANGHAI
PHARMACEUTICALS GROUP NEW HUALIAN PHARMACEUTICAL FACTORY which has long history.
Hence SC has certain amount of clients. |
|
|
The above information was confirmed by SC’s employee on Jun.27th,
2012. |
|
PURCHASE
INFORMATION
|
Main
Commodities Purchased |
Acetic
acid, perchloric acid, acetone, toluene, sulfuric acid, instruments,
production equipments, etc. |
|
Number
of Major Suppliers |
About
5 |
|
Region |
Domestic: 90% Import: 10% |
|
Major
suppliers |
SHANGHAI
XUNER NUANTONG EQUIPMENT SERVICE CO. LTD; JINAN YUANDONG ELECTRIC CABLE SALES
CO. LTD. |
|
Main
Terms of Payment |
Local: Prompt payment; on credit Import: L/C, T/T |
|
SC’s
raw materials are mainly purchased domestically. Some of its equipments are imported
from overseas countries. It has fixed suppliers and stable sources of goods. |
|
|
The
above information was confirmed by SC’s employee on Jun.27th,
2012. |
|
CREDIT
|
Name
of supplier |
JINAN YUANDONG ELECTRIC CABLE SALES CO. LTD. |
|
|
Main
commodities and service supplied |
Electric
cables. |
|
|
Interviewee |
Ms
Zhu of Sales Department. |
|
|
Telephone
of Interviewee |
86
531 87928388 |
|
|
Payment
comment |
The
investigated person confirmed SC is one of their clients and SC’s payment status
is good. |
|
|
|
|
|
|
Name
of supplier |
SHANGHAI XUNER NUANTONG EQUIPMENT SERVICE CO. LTD |
|
|
Main
commodities and service supplied |
Engineering
maintenance, etc. |
|
|
Interviewee |
Ms
Li of Sales Department. |
|
|
Telephone
of Interviewee |
86
21 68195089 |
|
|
Payment
comment |
The
investigated person confirmed SC is one of their clients and SC’s payment
status isn’t good. SC has been owing their company 30,000 CNY from 2011. |
|
LITIGATION
RECORDS
After checking
with China Court organization, the local court website and other major
searching websites, no litigation record related to SC in the latest three
years is found.
OTHER
ADVERSE MEDIA INFORMATION
|
Date |
Source |
Content |
|
Dec 13th, 2007 |
http://news.xinhuanet.com/legal/2007-12/13/content_7240833.htm |
SC’s predecessor company SHANGHAI PHARMACEUTICALS GROUP NEW HUALIAN
PHARMACEUTICAL FACTORY caused a serious pharmaceutical quality accident. |
FINANCE
SC’s Manager Pan was not clear about
its turnover. According to information obtained from public channels, SC’s
total assets and net assets were respectively 0.489 billion CNY and 0.109
billion CNY by the end of September, 2011. Its turnover and net profit of the
first 3 quarters in 2011 were respectively 83,667,500.00 CNY and 3,780,500.00
CNY.
Important Ratios:
|
|
2010
Industry Financial Indices |
|
Return on net assets (%) |
6.90 |
|
Return on total assets (%) |
6.30 |
|
Gross Profit Margin (%) |
24.50 |
|
Turnover of total assets |
1.10 |
|
Turnover of current assets |
1.60 |
|
Turnover days of account receivable |
50.00 |
|
Asset liability ratio (%) |
56.80 |
|
Current ratio |
1.22 |
|
Quick ratio |
0.76 |
Analysis of financial indicator
SC
mainly deals with manufacture and sales of bulk pharmaceutical chemicals,
tablets, capsules, etc and belongs to chemical medicine preparation manufacture
industry. Chemical medicine preparation occupies large shares in clinical
medications. The sustainable development of chemical medicine preparation
industry is key to the development of the whole pharmaceutical industry. The
chemical medicine preparation industry has bright prospect. Although
established in 2010, SC has advanced pharmaceutical equipments and testing
methods. Its employees are experienced professionals who have been working in
this industry for many years. SC’s location Shanghai City is a highly developed
city with stable foreign trade platform. SC’s overall economy environment is
satisfactory. As a domestic joint venture, SC’s financing capacity needs to be
improved.
INDUSTRY
PROFILE
Industry
SIC Code (China): 2720 manufacture of chemical
medicine preparation
Description:
manufacture of chemical medicines that are used to prevent and cure diseases.
Status Quo & Trend
Medicine preparation, chemical medicine
material and biological product manufacture are the 3 major components of
Chinese medicine manufacture industry, with medicine preparation being the
dominant part. However, so far in China, most enterprises are only producing
generic drugs instead of self innovation. In the future, the government would
increase investment in the technology improvement of the industry in order to
strengthen the competitiveness of Chinese medicine preparation industry.
Industry Associations
|
Name
of association |
Membership
of subject (Yes/No) |
|
China
Chemical Pharmaceutical Industry Association |
Not
Known |
|
China Biochemical Pharmaceutical Industry
Association |
Not Known |
|
China
Traditional Chinese Medicine Association |
Not Known |
|
International
Pharmaceutical Engineering Association |
Not Known |
GENERAL
COMMENTS
Established in November, 2010,
SC is engaged in manufacture and sales of bulk pharmaceutical chemicals,
tablets, capsules, oral solid ferment preparation, etc. Its products are mainly
sold to domestic and overseas pharmaceutical factories, hospitals,
distributors, chain drug stores, etc. SC’s predecessor company is SHANGHAI
PHARMACEUTICAL GROUP NEW HUALIAN PHARMACEUTICAL FACTORY which has long history.
Hence it has accumulated abundant industry experience. Its employees are mostly
experienced professionals who have been working in this period for many years.
SC has its own stable purchase and marketing channels. It has offices and
distributors in many domestic cities. SC enjoys certain popularity in the local
industry.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.56.91 |
|
|
1 |
Rs.88.90 |
|
Euro |
1 |
Rs.56.91 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.